Is Johnson & Johnson Heading Off The Patent Cliff?
Seeking Alpha
Can New Psoriasis Drugs Scratch Investors' Itch?
Investors.com
Can JAK Inhibitors Challenge Biologics?
Motley Fool
Merck's Weakest Blockbuster?
Motley Fool
Can Ampio's New Science Take A Big Bite Out Of The $60 Billion Anti-Inflammatory Market?
Seeking Alpha
Will New RA Therapies Cause a Paradigm Shift?
Pharma Live
Why Merck May Stagnate In 2012
Seeking Alpha